| Date | Title | Description |
| 15.08.2026 | Nvidia just updated its stock portfolio |
Nvidia (NASDAQ: NVDA) has updated its stock portfolio, revealing a public equity portfolio worth approximately $63.4 billion as of June 30, 2026, according to a Form 13F filing.
The filing highlights a dramatic increase from the previous q... |
| 03.03.2026 | Diversity will define the next era of biotech infrastructure | - |
| 27.02.2026 | Generate Biomedicines goes public with $400M to accelerate AI-driven drug discovery | - |
| 01.12.2025 | Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI | SOLAIRIA-1 and SOLAIRIA-2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains inadequately controlled on current therapies
These are the first global Phase 3 studies of a long-acting anti-TSLP anti... |
| 07.05.2025 | Flagship Pioneering, the National University of Singapore, National University Hospital and the National University Health System Announce Collaboration to Advance Biotech Research & Development | Collaboration Aims to Expand Globally Connected Scientific Dialogue and Accelerate Innovation in Human Health and Sustainability
SINGAPORE, May 7, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, the Yong Loo Li... |
| 18.12.2024 | Samsung's Bold Leap into Biomedicine: A New Era of AI-Driven Therapeutics | In the fast-paced world of biomedicine, Samsung is making waves. The tech giant has set its sights on revolutionizing the biopharmaceutical landscape through strategic investments and a commitment to sustainability. With its recent investme... |
| 18.12.2024 | Samsung Invests in Generate: Biomedicines | Generate: Biomedicines, a Somerville, MA-based clinical stage company which specializes in generative biology, received an investment from Samsung.
The amount of the deal was not disclosed.
The company intends to use the funds to expand ope... |
| 18.12.2024 | Samsung invests in Generate: Biomedicines to advance AI-driven protein therapeutics discovery | - Samsung Life Science Fund invests in Generate:Biomedicines, a Flagship Pioneering company leading in AI-enabled protein therapeutics discovery and development
- Investment highlights Samsung's dedication to advancing innovation and creati... |
| 03.10.2024 | A*STAR and Flagship Pioneering Announce Partnership to Spur Biotech Innovation in Singapore | Organizations Plan to Jointly Advance Breakthrough Solutions in Human Health and Sustainability, Drive Research Collaboration, Entrepreneurship and Accelerate Talent Development
SINGAPORE, Oct. 3, 2024 /PRNewswire/ -- The Agency for Science... |
| 28.08.2024 | Flagship Pioneering and Quotient Therapeutics Announce Agreement to Identify Potential Novel Targets for the Treatment of Cardiovascular and Renal Diseases under Strategic Partnership with Pfizer | Collaboration leverages Quotient's platform to identify somatic mutations in genes that modify the progression of cardiovascular and renal diseases
Quotient and Pioneering Medicines, Flagship's in-house drug development unit, will jointly c... |
| 06.08.2024 | Flagship Pioneering Announces Appointment of Raj Panjabi as Senior Partner | Former White House Top Health Security Official to Lead Flagship's Preemptive Health and Medicine Initiative
CAMBRIDGE, Mass., Aug. 6, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that global... |
| 11.06.2024 | SITC Announces Keynote Speaker Dr. Ignacio Melero at the Immuno-oncology Drug Development Summit | SITC IO Drug Development Keynote Speaker
The Society for Immunotherapy of Cancer (SITC) is excited to announce that Ignacio Melero, MD, PhD from the Clinica Universidad de Navarra Medical School and Cima will present his keynote on Cancer I... |
| 16.09.2023 | USA-based Generate:Biomedicines closes Series C financing at USD 270 million | Somerville, USA-based clinical-stage biotherapeutics company pioneering a machine-learning-powered generative biology platform, Generate: Biomedicines, closes Series C financing at USD 270 million. The company announced the fundraise on Sep... |
| 15.09.2023 | Generate:Biomedicines Closes $273M Series C Financing | Generate:Biomedics, a Somerville, MA-based clinical-stage biotherapeutics company, raised $273M in Series C funding.
Backers included Amgen, NVentures, MAPS Capital (Mirae Asset Group), and Pictet Alternative Advisors. Additionally, company... |
| 28.04.2023 | Biomedicines and MD Anderson Enter Co-Development and Commercialization Agreement to Accelerate Novel Protein Therapeutics for Oncology Using Generative AI | Generate:Biomedicines and The University of Texas MD Anderson Cancer Center announced a strategic collaboration to jointly discover and co-develop protein therapeutics for up to five oncology targets in advanced cancers, including small-cel... |
| 05.12.2022 | Вдохновлено DALL-E: как биолаборатории используют ИИ для изобретения новых лекарств | Недавно сразу две лаборатории независимо друг от друга представили программы на базе диффузионных моделей, которые позволяют создавать новые белки, значительно повышая точность результата.
Программа Chroma, разработанная бостонским стартапо... |
| 11.08.2022 | Prellis Biologics hires new CEO, raises $35M towards 3D bioprinted lymph node R&D | Prellis Biologics has raised $35 million and appointed a new CEO as it seeks to advance the development of its proprietary 3D bioprinted lymph node.
Raised via a Series C funding round led by Celesta Capital and Avidity Partners, and backed... |
| 01.12.2021 | Digital health news, funding roundup in the prior week; November 29, 2021 | Amazon Health sells healthcare services to Hilton; Athenahealth acquired for $17 Billion
Where tech meets weight and mental health. Mental health struggles and unintentional weight fluctuations are strongly linked. Experts state that stress... |
| 24.11.2021 | Generate Biomedicines Raises $370M in Series B Funding Round | Generate Biomedicines, a Cambridge, MA-based provider of a drug generation platform, raised $370M in Series B funding round.
The financing round included the company’s founder, Flagship Pioneering, along with several institutional co-invest... |
| 19.11.2021 | Generate Biomedicines hauls in $370M Series B | Generate Biomedicines has raised $370 million from investors including Flagship Pioneering, Altitude Life Science Ventures and Arch Venture Partners. Based in the Boston area, the company is using machine learning to develop new protein the... |
| 18.11.2021 | VC crypto funds are getting bigger. So are the opportunities | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Good morning, Term Sheet readers. Finance reporter Anne Sraders here, filling in for Lucinda.
Pai... |
| 18.11.2021 | VC crypto funds are getting bigger. So are the opportunities | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Good morning, Term Sheet readers. Finance reporter Anne Sraders here, filling in for Lucinda.
Pai... |
| 18.11.2021 | Generate Biomedicines Announces First External Equity Raise of $370 Million to Advance Its Drug Generation Platform | Generate Biomedicines, whose machine learning-powered Generative Biology platform can rapidly invent new drugs across a wide range of protein modalities and previously undiscoverable protein therapeutics, today announced it has raised $370 ... |
| 18.11.2021 | Generate Biomedicines raises $370M Series B with a focus on protein-based drugs | The drug development space is continuing to attract more and more investment. On Thursday, another major player, Generate Biomedicines, announced a $370 million Series B round.
Generate Biomedicines is touting a platform-based approach to d... |
| 18.11.2021 | Generate Biomedicines raises $370m and plans to increase workforce sixfold | Cambridge biotech Generate Biomedicines said Thursday it has raised $370 million in venture capital from investors keen on its plan to use machine learning in drug discovery, money that will enable the startup to expand its workforce more t... |
| - | Machine-Learning-Powered Generative Biology: Mirae Asset Group Joins $273M Funding Round for Generate:Biomedicines | Mirae Asset Global Investments has participated in a $273 million in Series C financing for Generate:Biomedicines, a clinical-stage biotherapeutics company pioneering a machine-learning-powered generative biology platform. Orrick advised Mi... |
